Difference between revisions of "Eculizumab (Soliris)"
m |
|||
| Line 23: | Line 23: | ||
* 3/16/2007: Initial approval for the treatment of patients with [[Paroxysmal_nocturnal_hemoglobinuria | paroxysmal nocturnal hemoglobinuria (PNH)]] to reduce hemolysis. ''(Based on SHEPHERD & TRIUMPH)'' | * 3/16/2007: Initial approval for the treatment of patients with [[Paroxysmal_nocturnal_hemoglobinuria | paroxysmal nocturnal hemoglobinuria (PNH)]] to reduce hemolysis. ''(Based on SHEPHERD & TRIUMPH)'' | ||
* 9/23/2011: Additional indication for the treatment of patients with [[Atypical hemolytic uremic syndrome|atypical hemolytic uremic syndrome (aHUS)]] to inhibit complement-mediated thrombotic microangiopathy. ''(Based on C08-002, C08-003, C10-004)'' | * 9/23/2011: Additional indication for the treatment of patients with [[Atypical hemolytic uremic syndrome|atypical hemolytic uremic syndrome (aHUS)]] to inhibit complement-mediated thrombotic microangiopathy. ''(Based on C08-002, C08-003, C10-004)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *6/20/2007: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Soliris | *'''Brand name:''' Soliris | ||
| Line 41: | Line 42: | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
| + | [[Category:EMA approved in 2007]] | ||
[[Category:FDA approved in 2007]] | [[Category:FDA approved in 2007]] | ||
Revision as of 13:28, 31 December 2022
General information
Class/mechanism: Complement inhibitor; monoclonal antibody that binds to complement protein C5, preventing its cleavage to C5a and C5b and the formation of the terminal complement complex C5b-9. Eculizumab is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS).[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Toxicity management
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Eculizumab (Soliris) package insert[1]
- Eculizumab (Soliris) patient drug information (Chemocare)[5]
- Eculizumab (Soliris) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 3/16/2007: Initial approval for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. (Based on SHEPHERD & TRIUMPH)
- 9/23/2011: Additional indication for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. (Based on C08-002, C08-003, C10-004)
History of changes in EMA indication
- 6/20/2007: Initial authorization
Also known as
- Brand name: Soliris
References
- ↑ 1.0 1.1 1.2 Eculizumab (Soliris) package insert
- ↑ Eculizumab (Soliris) package insert (locally hosted backup)
- ↑ Soliris manufacturer's website
- ↑ Soliris Risk Evaluation and Mitigation Strategy (REMS) Site
- ↑ Eculizumab (Soliris) patient drug information (Chemocare)
- ↑ Eculizumab (Soliris) patient drug information (UpToDate)